Digital Transformation in Healthcare: Mastering Efficiency and Innovation
Pharma IQ
SEPTEMBER 5, 2024
Explore how digital transformation, particularly cloud technology and AI enhances efficiency and patient outcomes.
Sat.Aug 31, 2024 - Fri.Sep 06, 2024
204 
AstraZeneca staffers detained in China over patient data collection, drug imports: Bloomberg
Fierce Pharma
SEPTEMBER 5, 2024
AstraZeneca has found its employees’ practices under the microscope of Chinese law enforcement years after an insurance fraud case. | AstraZeneca has found its employees’ practices under the microscope of Chinese law enforcement years after an insurance fraud case.
Join 8,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
China detains AstraZeneca workers in data, imports probe
pharmaphorum
SEPTEMBER 5, 2024
A "small number" of AstraZeneca employees have been detained in China in an investigation into suspected data privacy and drug import breaches
MedCity FemFwd: Inside WHAM & KPMG’s Women’s Health Partnership
MedCity News
SEPTEMBER 4, 2024
In this episode, we’re joined by Carolee Lee, CEO and founder of Women’s Health Access Matters (WHAM), and Ash Shehata, KPMG U.S. sector leader for healthcare. The two discuss WHAM and KPMG’s new partnership that aims to advance women’s health research and investment. The post MedCity FemFwd: Inside WHAM & KPMG’s Women’s Health Partnership appeared first on MedCity News.
AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
FDA grants ODD to Abdera’s neuroendocrine carcinoma treatment
Pharmaceutical Technology
SEPTEMBER 6, 2024
The US FDA has granted orphan drug designation (ODD) to Abdera Therapeutics’ ABD-147 aimed at neuroendocrine carcinoma.
In Europe, shortages of Novo Nordisk's Ozempic to persist into Q4: letter
Fierce Pharma
SEPTEMBER 3, 2024
Late last year, Novo Nordisk responded to a growing shortage of popular Ozempic with a plan to cut down on production of its older diabetes med Victoza to make room for more Ozempic. | The company and the European Medicines Agency warned European healthcare providers to continue limiting new patient prescriptions until the shortages let up.
Sign up to get articles personalized to your interests!
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
More Trending
With Direct-to-Patient Zepbound, Eli Lilly Takes a Stand Against Compounders and PBMs
MedCity News
SEPTEMBER 4, 2024
Eli Lilly now offers vials of obesity medication Zepbound directly to self-pay patients at a nearly 50% discount off the drug’s list price. But more than offering patients a lower-cost alternative, this move represents a strategic stance against certain pharmaceutical industry players. The post With Direct-to-Patient Zepbound, Eli Lilly Takes a Stand Against Compounders and PBMs appeared first on MedCity News.
It’s All About the Small Things
PharmaTech
SEPTEMBER 5, 2024
Qualifying material suppliers is a crucial step in ensuring safe and effective drug products.
J&J bolsters Rybrevant-Lazcluze's case against AZ's Tagrisso with survival analysis
Fierce Pharma
SEPTEMBER 5, 2024
Johnson & Johnson’s newly FDA-approved lung cancer combination of Rybrevant and Lazcluze is inching ever closer to a statistically significant survival showing, which could help it better chall | Johnson & Johnson’s newly FDA-approved lung cancer combination of Rybrevant and Lazcluze is inching ever closer to a statistically significant survival showing, which could help it better challenge AstraZeneca’s Tagrisso.
Advanz wins stay on EU revocation of Ocaliva license
pharmaphorum
SEPTEMBER 5, 2024
EU General Court suspends decision to revoke the license for Advanz Pharma's primary biliary cholangitis drug Ocaliva.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
What Challenges Do Implementing New Tech at a Hospital Pose?
MedCity News
SEPTEMBER 5, 2024
Cyril Philip, vice president of digital health ventures with Bon Secours Mercy Health and digital ventures lead for Accrete Health Partners, is taking part in a panel discussion at INVEST Digital Health in Dallas on September 18. In response to emailed questions, he addressed some of these challenges. The post What Challenges Do Implementing New Tech at a Hospital Pose?
Unpacking the High Cost of GLP-1 Drugs
Pharmaceutical Commerce
SEPTEMBER 3, 2024
How can industry stakeholders ensure the quality and supply chain security of existing product?
GSK posts COPD win for Nucala as Sanofi-Regeneron rival Dupixent nears delayed FDA decision
Fierce Pharma
SEPTEMBER 6, 2024
GSK is heading into the weekend with a win for its respiratory blockbuster Nucala—but for now, the details are slim. | On Friday, GSK said that its IL-5 antibody Nucala plus inhaled maintenance therapy lowered the annualized rate of moderate or severe exacerbations among chronic obstructive pulmonary disease (COPD) patients for up to 2 years. Nucala is already approved in a range of respiratory conditions, but a COPD nod could present another big opportunity for the drug.
Illumina avoids hefty EU fine over Grail merger
pharmaphorum
SEPTEMBER 3, 2024
EU had no grounds to probe Illumina's takeover of Grail, says ECJ, but while spinoff has already taken place Illumina can now avoid a €432m fine
What Do Consumers and AI Think Of Omada Health?
MedCity News
SEPTEMBER 5, 2024
Omada Health is a respected health tech company but what do customers see it? A flesh and blood and an AI analysis follows. The post What Do Consumers and AI Think Of Omada Health? appeared first on MedCity News.
First-in-class combination therapy authorised for endometriosis
European Pharmaceutical Review
SEPTEMBER 5, 2024
The Medicines and Healthcare Products Regulatory Agency (MHRA) has licenced the first treatment (oral gonadotropin-releasing hormone [GnRH] receptor antagonist) in a new class of medicines for women in the UK with endometriosis. Relugolix combination therapy, Ryeqo (relugolix 40mg, estradiol 1mg, and norethisterone acetate 0.5mg), is authorised to treat endometriosis symptoms in adults.
Gilead's Trodelvy triplet underwhelms, but bolsters company's phase 3 lung cancer design: exec
Fierce Pharma
SEPTEMBER 6, 2024
Gilead Sciences has been looking for a win for Trodelvy after two surprise trial failures earlier this year. | Gilead Sciences has been looking for a win for Trodelvy after two surprise trial failures earlier this year. But it looks like that win won’t come from a triplet regimen that combines the antibody-drug conjugate with Merck’s Keytruda and chemotherapy in newly diagnosed non-small cell lung cancer.
Alnylam hails vutrisiran data, but investors seem sceptical
pharmaphorum
SEPTEMBER 1, 2024
Alnylam Pharma has been riding high since revealing top-line results from its HELIOS-B trial of vutrisiran in transthyretin-mediated amyloidosis (ATTR) – but a look at the full data seems to have disappointed investors.Shares in the company retreated after the presentation of the results at the European Society of Cardiology (ESC) conference, which confirmed a 28% reduction in the primary endpoint of deaths from any cause and recurrent cardiovascular events after at least 33 months of follow-up.
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
SEQSTER, PatientsLikeMe Launch Patient Data Partnership
MedCity News
SEPTEMBER 5, 2024
Through a new partnership announced Thursday, SEQSTER will be PatientsLikeMe’s electronic health record provider. The post SEQSTER, PatientsLikeMe Launch Patient Data Partnership appeared first on MedCity News.
Aptose Biosciences secures funds for AML treatment development
Pharmaceutical Technology
SEPTEMBER 2, 2024
Aptose Biosciences has secured a loan of $10m through a facility agreement with Hanmi Pharmaceutical to develop tuspetinib.
Biogen to seek approval for high-dose version of SMA stalwart Spinraza after trial win
Fierce Pharma
SEPTEMBER 4, 2024
Over the last decade, three blockbuster drugs—Biogen’s Spinraza, Roche’s Evrysdi and Novartis’ gene therapy Zolgensma—have transformed the treatment landscape for spinal muscular atrophy (SMA). | Biogen revealed that a portion of its phase 2/3 DEVOTE study met its primary endpoint, as a higher dose of Spinraza improved the motor function of treatment-naive infants with spinal muscular atrophy.
BioAge's $100m IPO, and other biotech financings
pharmaphorum
SEPTEMBER 6, 2024
Financings in the biotech sector this week include an IPO filing for BioAge and private rounds for eGenesis, Navigator, and Circle Pharma.
How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
Can AI Help Fix Our Demographic Time Bomb?
MedCity News
SEPTEMBER 6, 2024
By 2030, the U.S. expects shortages of 200,000 nurses and 124,000 physicians snd similar shortages are already being felt in the U.K. and elsewhere. Here’s how to build and train a modern healthcare workforce in the age of AI The post Can AI Help Fix Our Demographic Time Bomb? appeared first on MedCity News.
Eli Lilly’s once-weekly insulin shows promise in phase 3 trials
PharmaTimes
SEPTEMBER 6, 2024
New treatment could simplify diabetes management for millions
Astellas Gene Therapies to turn out the lights at South San Francisco production plant
Fierce Pharma
SEPTEMBER 4, 2024
Several months after its parent company unveiled new labs and office space to unite cell and gene therapy research on the West Coast, Astellas Gene Therapies is turning out the lights at a Californ | Several months after its parent company unveiled new labs and office space to unite cell and gene therapy research on the West Coast, Astellas Gene Therapies is turning out the lights at a California production plant.
GSK says Nucala hits the target in new COPD trial
pharmaphorum
SEPTEMBER 6, 2024
GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial.
How to Stay Competitive in the Evolving State of Martech
Advertiser: ZoomInfo
Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr
Full FDA Approval of Travere’s Kidney Drug Stiffens Competition With Novartis, Calliditas
MedCity News
SEPTEMBER 6, 2024
The FDA decision for Travere Therapeutics’ Filspari also expands its addressable patient population. The full approval comes nearly a year after the Travere drug narrowly missed the main goal of its confirmatory study. The post Full FDA Approval of Travere’s Kidney Drug Stiffens Competition With Novartis, Calliditas appeared first on MedCity News.
UAE MoHAP and Novo Nordisk partner for obesity management
Pharmaceutical Technology
SEPTEMBER 3, 2024
The UAE has partnered with Novo Nordisk Pharma Gulf to develop a national scientific guide for obesity management and weight control.
Cash-crunched ImmunityBio, on heels of FDA nod for Anktiva, lays off staffers
Fierce Pharma
SEPTEMBER 5, 2024
With dwindling funds after a prior snub from the FDA, ImmunityBio’s journey to bag approval for its Merck-rivaling bladder cancer drug Anktiva wasn’t easy. | The drugmaker laid off 20 employees as it attempts to recoup from dwindling funds during its Anktiva launch in bladder cancer.
ArsenalBio raises $325m for programmable CAR-T platform
pharmaphorum
SEPTEMBER 5, 2024
ArsenalBio raises $325m for programmable CAR-T platform Phil.
Let's personalize your content